Householder Group Estate & Retirement Specialist LLC Has $47,000 Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Householder Group Estate & Retirement Specialist LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 94.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 90 shares of the medical research company's stock after selling 1,527 shares during the period. Householder Group Estate & Retirement Specialist LLC's holdings in Thermo Fisher Scientific were worth $47,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in TMO. Legacy Investment Solutions LLC bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $26,000. Peterson Financial Group Inc. bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $27,000. RPg Family Wealth Advisory LLC bought a new position in shares of Thermo Fisher Scientific in the third quarter worth $50,000. Decker Retirement Planning Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $43,000. Finally, HWG Holdings LP acquired a new stake in Thermo Fisher Scientific in the second quarter worth about $50,000. 89.23% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,150 shares of company stock valued at $25,954,465. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $1.99 during midday trading on Friday, hitting $559.72. 2,134,669 shares of the company traded hands, compared to its average volume of 1,426,114. The business has a 50 day simple moving average of $529.96 and a 200-day simple moving average of $568.33. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The stock has a market capitalization of $214.09 billion, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 3.59 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business's revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.69 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has authorized a share buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is currently 9.78%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TMO. Morgan Stanley reduced their price target on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an "overweight" rating for the company in a research note on Monday, January 13th. Barclays decreased their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 23rd. Redburn Atlantic started coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a "buy" rating and a $680.00 price objective on the stock. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. Finally, Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price on the stock in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $648.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.